T2 Biosystems (TTOO) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary

Market need and clinical impact

• Sepsis is the leading cause of death and hospitalization costs in US hospitals, with $62 billion in annual costs and 350,000 deaths per year.

• High rates of rehospitalization among sepsis survivors highlight failures in current care standards.

• Rapid, targeted antimicrobial therapy is critical, as each hour of delay increases mortality risk by up to 8%.

Technology and competitive differentiation

• Magnetic resonance technology enables direct pathogen detection in blood, bypassing the need for positive blood cultures.

• Competitors require days for blood culture results, limiting clinical utility, especially during supply shortages.

• Strong intellectual property covers both detection and sample processing methods.

Commercialization and global expansion

• Early commercialization stage with about 200 instruments installed, split between US and Western Europe.

• Distribution network covers 45 countries, with major partners in Spain, Portugal, Italy, and Eastern Europe.

• Asia-Pacific, especially China and India, represents significant untapped market potential.